Ozempic's published US list price is $1,027.51 for a one-month supply — identical for the 0.25 mg, 0.5 mg, 1 mg and 2 mg pens and for every tablet strength (Novo Nordisk's own list-price page, checked 13 July 2026). Hardly anyone pays it. If you have commercial insurance that covers Ozempic, the manufacturer savings card can bring your copay to as little as $25 a month — capped at $100 of savings a month. If you are paying cash, the manufacturer's self-pay prices run $199 to $499 a month for the pen and $149 to $299 for the pill. And if you are on Medicare or Medicaid, the savings card is off the table entirely — that is the single most common and most painful surprise.
These three numbers — list, insured copay, cash — get blended together in almost every article on this subject, which is why people walk into a pharmacy expecting $25 and get told $1,027. Below, we separate them, and we say plainly where the honest answer is "your plan decides and we cannot know it."
The three numbers, kept apart
| Number | What it is | Amount | Who actually pays it |
|---|---|---|---|
| List price (WAC) | What the manufacturer publishes to wholesalers. It sets no one's copay directly, but it is the starting point insurers negotiate from. | $1,027.51 per month — the same figure for every pen strength and every tablet strength | Almost no one pays it in full — but people with a high deductible or percentage coinsurance can be exposed to something close to it early in the year. |
| Insured copay with savings card | What you pay at the counter when your commercial plan covers Ozempic and you apply the manufacturer's savings offer. | "As little as $25" for any dose, for a prescription of up to three months — subject to a maximum saving of $100 per month, for up to 48 months | People with commercial (employer or marketplace) insurance that already covers Ozempic. Government beneficiaries are excluded. |
| Cash / self-pay price | Manufacturer direct pricing, through NovoCare Pharmacy or the federal TrumpRx.gov storefront. | Pen: $199/month for the first two fills of 0.25 mg or 0.5 mg (patients new to the offer, through 31 Dec 2026), then $349/month for 0.25–1 mg and $499/month for 2 mg. Pill: $149 (1.5 mg), $199 (4 mg), $299 (9 mg) | Anyone with a valid prescription who is paying out of pocket, including people whose insurance refuses to cover it. |
Note what the $25 figure really is. The savings card carries a maximum saving of $100 a month. It discounts your copay by up to $100 — it does not magic a $600 coinsurance bill down to $25. If your plan covers Ozempic with a flat $60 tier-3 copay, the card is genuinely powerful. If your plan applies 30% coinsurance against the list price, the card takes $100 off and you still face a large bill. Read your plan's benefit design, not the marketing.
The coverage question that decides everything: what is it for?
Ozempic's FDA label covers three things in adults with type 2 diabetes: improving blood sugar alongside diet and exercise, reducing the risk of major cardiovascular events in people who also have established cardiovascular disease, and slowing kidney decline in people who also have chronic kidney disease. Weight loss is not on that label. Semaglutide is approved for chronic weight management — but under a different brand (Wegovy), at different doses.
That single fact drives most denials. Plans check the diagnosis attached to the prescription. If it is type 2 diabetes, Ozempic is usually on the formulary (often with prior authorisation, sometimes with a step through metformin first). If it is obesity or "weight loss," most plans treat Ozempic as off-label and decline — not because your prescriber did anything wrong, but because the plan buys coverage by indication. A denial here is a formulary rule, not a judgement about you. If weight management is the goal, the honest conversation with your prescriber is about which product is actually indicated for it; our comparison of Wegovy vs Ozempic and Mounjaro vs Ozempic lays out the differences.
We will never coach anyone to describe their situation to an insurer as anything other than what it is. Misrepresenting a diagnosis is insurance fraud and it puts your prescriber's licence at risk too.
Every route to a lower price, and who it is actually open to
| Route | Roughly what you pay | Open to | The catch |
|---|---|---|---|
| Manufacturer savings card (Ozempic Savings Offer) | As little as $25 for any dose, max saving $100/month, for up to 48 months | US residents with commercial insurance that covers Ozempic | Government beneficiaries excluded — Medicare, Medicaid, TRICARE, VA. Novo states that if you hold both a commercial and a government-funded plan, you count as a government beneficiary. The discount also does not count toward your deductible or out-of-pocket maximum. |
| NovoCare Pharmacy self-pay (direct from manufacturer, home delivery or local pickup) | Pen: $199/month for the first two fills of 0.25 or 0.5 mg for patients new to the offer, then $349/month (0.25–1 mg) or $499/month (2 mg). Pill: $149/month (1.5 mg), $199 (4 mg), $299 (9 mg) | Anyone paying cash with a valid prescription — including Medicare enrollees, who may pay cash instead of using their plan | Cash spending does not count toward a Part D deductible or the annual out-of-pocket cap. The introductory $199 tier is time-limited (two fills, through 31 Dec 2026), and Novo prints on the price guide itself that it "reserves the right to modify or cancel this program at any time." |
| TrumpRx.gov | Same manufacturer self-pay prices, routed through a federal storefront that hands you off to the manufacturer's pharmacy or issues a coupon for a participating pharmacy | Self-pay patients | It is a price-comparison and referral site, not an insurer and not a pharmacy. Same caveat: it is not creditable coverage and does not count toward Medicare out-of-pocket totals. |
| Medicare Part D | Whatever your plan's tier says; in 2026 the Part D deductible can be up to $615 and out-of-pocket spending is capped at $2,100 for the year | Part D enrollees whose plan covers Ozempic — realistically, when it is prescribed for type 2 diabetes | The savings card is unusable. Once you hit the $2,100 cap you pay $0 for covered drugs for the rest of the year — which is why running the drug through the plan sometimes beats a cheaper-looking cash price. |
| Medicare GLP-1 Bridge ($50/month demonstration, 1 July 2026 – 31 Dec 2027) | $50/month flat, in every benefit phase | Part D enrollees who meet BMI and clinical criteria, with prescriber attestation — for weight reduction and maintenance | It covers obesity-indicated products (Wegovy and certain other weight-management GLP-1s). Ozempic has no weight-loss indication, so it is not on the Bridge list. The $50 copay also does not count toward your Part D deductible or the $2,100 cap. Ask your prescriber whether an indicated product is appropriate for you. |
| Medicaid | Varies by state; typically a very low copay when covered | Medicaid enrollees | Coverage rules are state-by-state and generally hinge on diagnosis. The manufacturer card is excluded. |
| Pharmacy discount cards (GoodRx and similar) | Varies; for Ozempic these have generally sat well above the manufacturer's own self-pay price | Anyone | Compare against the manufacturer self-pay price before assuming a coupon site is cheaper. Discount-card spending does not count toward insurance out-of-pocket totals either. |
| Patient assistance (Novo Nordisk Patient Assistance Program) | Potentially $0 | Uninsured patients under published income thresholds | Income documentation and prescriber paperwork required; not instant. |
Disclosure: VidaBeacon may earn a commission if you use some links on this site to reach a care provider or product. It never changes what we print. Nothing in this article is a recommendation of any specific pharmacy, telehealth service or seller.
Why these numbers keep moving
GLP-1 pricing is being rewritten in public. Two changes matter for anyone budgeting past this year. First, Novo Nordisk has announced a cut to the US list price of its semaglutide medicines — Ozempic, Wegovy and Rybelsus — to $675 a month effective 1 January 2027, roughly a 35% reduction for Ozempic. Second, and less intuitively, the company has said that cut does not change the direct-to-patient self-pay prices; those channels stay where they are. So a lower list price mainly changes what happens to people exposed to list — high-deductible and coinsurance plans — rather than to cash buyers. Any figure in this article, ours included, should be re-checked on the manufacturer's page on the day you fill.
The Medicare trap, stated plainly
If you are on Medicare — including a Medicare Advantage plan with drug coverage — the $25 savings card is not available to you. This is not a loophole to be argued with; it follows from federal anti-kickback law, and the manufacturer applies the same exclusion to Medicaid, TRICARE and VA beneficiaries. Two consequences catch people:
- You can still pay cash. Medicare enrollees may buy at the manufacturer's self-pay price. Some do this deliberately when their plan does not cover the drug at all.
- Cash does not count. Dollars you spend outside the plan do not move you toward the 2026 Part D deductible (up to $615) or the $2,100 out-of-pocket cap. If your plan does cover Ozempic and you expect high drug spending this year, running it through the plan may cost less over twelve months than a cheaper-looking monthly cash price. Do the arithmetic for the full year, not the month.
If you are denied
A denial is a document, not a verdict. Ask the plan for the denial reason in writing — it will name the rule (not on formulary, prior authorisation required, step therapy, diagnosis not covered). Each rule has a different answer. Prior authorisation means your prescriber's office submits clinical notes; step therapy usually means documenting that a cheaper drug failed or is unsuitable; a formulary exclusion means asking for a formulary exception, which needs a clinical rationale. If the prescription is for weight loss and the plan covers Ozempic only for type 2 diabetes, no amount of paperwork changes that — the conversation to have is with your prescriber about a product that carries the indication you actually need. Commercial plans and Medicare both have appeal timelines; the denial letter states them, and missing them is the most common own goal.
What about compounded semaglutide?
Compounded semaglutide is not an FDA-approved product. Compounded drugs are not reviewed by the FDA for safety, effectiveness or manufacturing quality, and "compounded semaglutide" is not the same thing as Ozempic. The FDA declared the semaglutide shortage resolved in February 2025; once a drug is off the shortage list, compounding pharmacies may no longer make what the agency calls essentially a copy of it, and enforcement has continued since. Sellers still advertise cheap "semaglutide" online.
There is a documented, specific harm here worth naming, because it is not theoretical. Compounded product is typically supplied as a multi-dose vial with a syringe rather than a pre-set pen, and the FDA has received reports of overdoses — people confusing the "units" marked on an insulin syringe with millilitres and drawing up several times, in some cases roughly ten times, the intended dose, with vomiting, dehydration and hospital visits following. A pen doses itself; a vial does not.
We are not going to tell you to use or avoid compounded product — that is a decision for you and a clinician who knows your history. We will say this: do not buy from any source that will not show you a state pharmacy licence, will not put a licensed prescriber's name on your record, or ships from outside the US without one. You can check a pharmacy's licensure through the National Association of Boards of Pharmacy. Products bought outside a verified pharmacy carry no guarantee of what is in the vial.
If you are evaluating a telehealth service
Many people reach GLP-1 prescriptions through online clinics. We do not recommend a specific one. Judge any service on five things: (1) Does a licensed clinician in your state actually review you, and can you see their name and licence? (2) Are they prescribing an FDA-approved, brand-name product, or a compounded version — and do they say which, in writing, before you pay? (3) What is the total monthly cost including consult fees and shipping, not the headline price? (4) What happens if you stop — is there an auto-renewing subscription, and can you cancel in one click? (5) Is there any follow-up on side effects and labs, or does the relationship end at checkout? Our guide to online GLP-1 weight care walks through the same checks.
Dose and price: what the label says
Because Ozempic's list and self-pay prices are per pen rather than per milligram, cost does not rise evenly with dose — the 2 mg self-pay tier is $499 while everything below it is $349. That leads some people to ask about stretching or splitting pens. This section is reference, not instruction. The FDA label publishes a starting dose and an escalation schedule; your prescriber, not a website and not a cost table, sets your dose. Do not self-adjust. Do not stretch a pen to make it last. Do not double up after a missed dose. If cost is the reason you are considering any of that, say so to your prescriber — that sentence is exactly what opens the door to a covered alternative, a patient-assistance application or a different product. See our reference page on GLP-1 dosing schedules for what the labels publish.
When to talk to your prescriber
Make the call — do not just absorb the price — if any of these apply:
- You have been denied coverage. Get the reason in writing, then ask the office whether a prior authorisation or formulary exception is worth filing, and whether a covered alternative fits your diagnosis.
- You are rationing — skipping doses, delaying refills, or stretching a pen because of money. This is a clinical problem, not a budgeting one, and prescribers deal with it constantly.
- You are considering stopping. Never start or stop a prescription medicine on the basis of an article. Blood sugar, blood pressure and weight can all move when a GLP-1 is stopped; that needs a plan.
- You have persistent vomiting, severe abdominal pain radiating to the back, signs of dehydration, or vision changes — seek care promptly, regardless of cost. See Ozempic and Wegovy side effects.
- You have a personal or family history of medullary thyroid carcinoma or MEN 2 — the label lists these as contraindications.
The exact questions to ask
Call the member-services number on your insurance card and ask, in this order: Is Ozempic on my formulary? What tier, and is it a flat copay or coinsurance? Does it require prior authorisation, and what diagnosis codes will you accept? Is there a step-therapy requirement? What have I spent toward my deductible and my out-of-pocket maximum so far this year? Write down the answers and the reference number of the call. Those five answers, plus the tables above, tell you what Ozempic will cost you — which no article can. Our cost and coverage estimator helps you organise the answers.
Prices in this piece were checked on 13 July 2026 against Novo Nordisk's published list-price page and its NovoCare Ozempic price guide, CMS's 2026 Part D parameters and GLP-1 Bridge rules, and the FDA-approved prescribing information. Manufacturer offers change without notice — check the manufacturer's page for the figure on the day you fill. Related reading: how GLP-1 medicines work, Ozempic alternatives, and weight and metabolism.
